ImmunoGen, Inc. to Present at Needham & Company, LLC's Sixth Annual Biotechnology and Medical Technology Conference
CAMBRIDGE, Mass.--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at Needham & Company, LLC's Sixth Annual Biotechnology and Medical Technology Conference will be webcast live. The presentation is scheduled to begin at 10:30 am ET on Thursday, June 14, 2007, and will be given at the New York Palace Hotel in New York. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.
Contacts
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.
Contacts
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.